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Chronic hepatitis B (CHB) affects 350 million individuals worldwide. Perinatal transmission leads to high rates of chronic infection 
and complications, including cirrhosis and hepatocellular carcinoma. It is important to recognize and appropriately treat CHB in 
pregnancy, thereby reducing the risk of neonatal transmission and HBV-associated morbidity and mortality. Screening for CHB is 
recommended in all pregnant mothers as is universal vaccination of infants with hepatitis B virus (HBV) vaccine with or without 
hepatitis B immunoglobulin (HBIG). This has resulted in a lower incidence of HBsAg seropositivity and HCC in regions where 
universal infant vaccination has been endorsed. Mode of delivery and breastfeeding do not appear to affect HBV transmission 
rates based on available data. Overall, CHB does not increase perinatal maternal-fetal mortality. Administration of oral antiviral 
therapy during the third trimester to HBsAg-positive mothers with HBV DNA≥7 log IU/mL may be useful in preventing 
breakthrough infection. Treatment may be considered earlier in pregnancy for persistently active liver disease shown by high 
ALT, HBV DNA levels and/or significant hepatic fibrosis. Lamivudine, tenofovir and telbivudine are safe and effective and are the 
agents of choice in pregnancy. However, further clinical studies are necessary to elucidate the role of antiviral therapy in the 
pregnant HBV carrier. (Korean J Hepatol 2011;17:1-8)
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INTRODUCTION
Chronic hepatitis B (CHB) in pregnancy is a prevalent and 
important problem with unique challenges. Over 50% of the 
world’s 350 million carriers of CHB acquire the infection 
perinatally; in hepatitis B e antigen (HBeAg)-positive mothers, 
rates of transmission are as high as 90%.
1 The majority (> 95%) 
of perinatally acquired infection results in CHB infection, due to 
induction of an immune tolerant state of variable duration. 
Worldwide, CHB remains a major health threat; each year 
approximately 600,000 individuals die of complications such as 
acute liver failure, cirrhosis, and hepatocellular carcinoma 
(HCC).
2 Therefore, prevention of perinatal transmission remains 
an important target in the struggle for global eradication of 
hepatitis B virus (HBV) infection.
The prevalence of hepatitis B surface antigen (HBsAg)- 
positive pregnant individuals varies with geographic loca-
tion and ethnicity. In the USA, HBsAg prevalence is 6% in 
Asian women, 1% in African-Americans, 0.6% in non-Hispanic 
whites and 0.1% in Hispanics.
1 In endemic areas such as 
China and South East Asia, the prevalence may be as high as 
10-20%.
3  Due to recent immigration patterns in North 
America, country of birth as well as ethnicity are important 
risk factors for perinatal acquisition of HBV.
This review will focus on strategies aimed at decreasing 
maternal-fetal transmission of CHB. HBsAg screening, HBV 
vaccination, mode of delivery and breastfeeding, and oral 
antiviral prophylaxis will be discussed. Based on studies of 
antiviral agents in pregnancy, we propose an algorithm for 
the prevention of perinatal transmission of HBV.2  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011
Table 1. High risk groups for HBV screening as per AASLD
5
Individuals from endemic areas (Asia, Africa, South Pacific islands, South/Central America (certain countries), Caribbean, the Arctic
(including indigenous populations of Alaska, Canada, and Greenland), Middle East (certain countries), and Eastern Europe (certain 
countries)
Unvaccinated individuals whose parents were born in areas of high HBV endemicity
All household and sexual contacts of HBsAg-positive individuals
Injection drug users
Persons with multiple sexual partners
Persons in correctional facilities
Dialysis patients
Those with HCV or HIV
All pregnant women
Persons receiving immunosuppressive therapy
HBV, hepatitis B virus; AASLD, American Association for the Study of Liver Disease; HCV, hepatitis C virus; HIV, human 
immunodeficiency virus.
SCREENING 
Due to availability of a safe and effective vaccine against 
HBV, perinatal screening for HBV has become standard in 
perinatal care. Screening allows for identification of infants 
requiring immunoprophylaxis with HBV vaccine and hep-
atitis B immune globulin (HBIG), antiviral treatment of 
pregnant carriers if indicated, and counseling of sexual and 
household contacts.
1 
Universal screening as opposed to risk factor-based screening 
of all pregnant patients for hepatitis B is standard of care, 
since the latter results in missing as many as 50% HBsAg- 
positive individuals in some populations as shown by a 
study from Denmark.
4 Therefore, the American Association 
for the Study of Liver Disease (AASLD) recommends that 
all pregnant women be screened for HBsAg during the first 
trimester, even if previously vaccinated or tested.
5 Similarly, 
the US Preventive Services Task Force (USPSTF) recom-
mends screening at the first prenatal visit.
6 In practice, a 
positive HBsAg test must be communicated to the hospital 
where the patient intends to deliver, in order to allow for 
appropriate immunoprophylaxis. Furthermore, all HBsAg- 
positive pregnant carriers should ideally be referred for 
counseling and appropriate medical management. 
VACCINATION
Since the development of the recombinant HBV vacci-
nation in 1982, several health authorities, including the 
World Health Organization (WHO) recommend its use in 
infants born to mothers positive for HBsAg, in addition to 
other high-risk groups (Table 1). Globally, over 160 coun-
tries endorse universal infant vaccination, particularly in 
regions where HBV is endemic. WHO recommends the 1
st 
dose of HBV vaccine administered within 24 hours of birth 
and 2 to 3 subsequent doses as part of routine immunization 
schedules. Hepatitis B immunoglobulin (HBIG) passive 
immunization in conjunction with HBV vaccination may also 
be administered to infants born to HBeAg-positive mothers. 
However, WHO acknowledges the limitations related to cost 
and supply of HBIG in certain endemic areas.
2 The Centre 
for Disease Control (CDC) also advises one dose of HBV 
vaccine given shortly after birth with or without HBIG.
7 The 
USPSTF recommends administering the first dose of HBV 
vaccine and HBIG within 12 hours of birth.
8 Several studies 
have documented the benefits of such vaccination strategies 
in reducing HBsAg prevalence.
9-14
Beasley et al reported results of a randomized blinded 
controlled trial of HBIG plus HBV vaccine for the prevention 
of perinatal transmission in 172 infants of HBeAg- positive 
mothers followed for up to 2 years after birth. Overall, there 
was a significant difference in persistent HBsAg positivity 
in 6% (9/156) infants who received immunoprophylaxis 
compared to 88% historical controls. There was no difference 
in efficacy between combined HBIG and HBV vaccination 
(94%), compared to HBIG alone (71%), or HBV vaccination 
alone (75%).
9 A similar study by Wong et al. examined four 
vaccination schedules in 140 infants born to HBeAg-positive 
mothers. HBV vaccine was given at 0, 1, 2, and 6 months after 
birth. Persistence of HBsAg (≥ 6 months) was significantly Yogeswaran and Fung. Chronic hepatitis B in pregnancy: unique challenges and opportunities  3
Table 2. CDC vaccination schedule for HBV
7
At birth
Infants born to HBsAg-positive mothers require HBV vaccine and HBIG ≤ 12 hours after birth
If maternal HBsAg status is unknown, infants should receive HBV vaccine ≤ 12 hours after birth; 
Maternal HBsAg status should then be determined and if positive, infants should additionally receive HBIG ≤ 1 week after birth
In infants born to HBsAg-negative mothers, first HBV vaccine should be given before hospital discharge in full-term infants, and 
one month after birth or at hospital discharge in pre-term infants
After birth dose
All infants should complete the HBV vaccination series (typically two additional vaccines) as per locally recommended vaccination 
schedules
Infants born to HBsAg-positive mothers should be tested for HBsAg and anti-HBs levels following vaccination, typically at 9-18 
months
CDC, Centers for Disease Control; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HBIG, hepatitis B Immunoglobulin.
lower in the treatment groups receiving vaccination plus 7 
HBIG injections (2.9%), vaccination plus 1 HBIG injection 
(6.8%), and vaccination alone (21%), compared with placebo 
(73%, P<0.0001). Multiple HBIG injections did not appear 
to confer significant additional benefit.
10 A recent system-
atic review and meta- analysis of 29 randomized controlled 
trials reported an overall reduction in HBsAg seroprevalence 
using vaccine alone (RR=0.28) or in combination with HBIG 
(RR=0.08) compared to placebo. However, only a small 
number of high quality trials were included in these reviews 
and most studies (62%) included only HBeAg-positive 
mothers.
11
Despite the limitations of published trials, universal vac-
cination schedules have been widely accepted and im-
plemented to decrease the risk of perinatal transmission, and 
ultimately, the global burden of disease (Table 2). Long-term 
follow-up studies from Taiwan, where vaccination has been 
in place for more than 20 years, have shown significant 
decreases in perinatal transmission rates and complications 
of CHB, including acute infection and HCC.
12,13 Chang et al 
demonstrated that the incidence of HCC in Taiwan decreased 
in children aged 6-14 years from 0.70/100,000 (1981-1986) 
to 0.36/100,000 (1990-1994) (P<0.01).
12  Although these 
studies suggest that universal infant vaccination is effective, 
not all infants respond to vaccine and chronic infection has 
been reported in 1-10% infants despite immunization due to 
breakthrough infection.
11,14
ROLE OF ANTIVIRAL THERAPY
Risk factors for perinatal transmission of HBV include 
HBeAg-positive status and high HBV DNA, usually ≥10
8 
copies/mL.
1 The role of other factors such as viral genotype 
and mutation remain unclear. Strategies to prevent break-
through infection despite vaccination include administration 
of HBIG during pregnancy and shortly after birth. More 
recently, nucleos(t)ide antiviral therapy such as lamivudine 
has been studied, analogous to the situation in human 
immunodeficiency virus (HIV)-infected pregnant women.
The role of antiviral therapy in pregnant HBV carriers has 
been addressed in a small number of studies. One small 
study included 8 HBeAg-positive mothers with high viral 
loads (≥1.2×10
9 geq/mL) who were treated with lamivudine 
150 mg daily from 34 weeks gestational age to delivery 
compared to 24 infants born to untreated HBeAg-positive 
mothers who served as controls. All mothers received 
passive and active immunization. In the treatment group, 
only 1 (12.5%) infant remained HBsAg-positive at one year 
compared to 28% infants in the control group. HBV DNA 
declined by 1 log genome equivalents per mL (geq/mL) or 
more in 5 (63%) infants in the treated group (duration 6-40 
days). No adverse events were reported in this small trial, 
suggesting that lamivudine was safe and effective in inter-
rupting perinatal HBV transmission.
15
A large randomized placebo-controlled double-blind 
study of 155 HBeAg-positive women with HBV DNA≥1,000 
Meq/ml but mainly normal ALT compared lamivudine 100 
mg daily to placebo (Table 3). 141 infants received immuno-
prophylaxis, but only 115 who received both HBV vaccine 
and HBIG were included in the final analysis. Mothers 
randomized to lamivudine received treatment beginning at 
32 weeks gestational age and ending at 4 weeks post partum. 
At 52 weeks post partum, 10/56 (18%) infants born to lamivudine- 
treated mothers remained HBsAg-positive compared to 4  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011
Table 3. Maternal baseline characteristics and outcomes in infants of mothers receiving lamivudine compared with placebo
16
Lamivudine+vaccine+HBIG (n=56)
* Placebo+vaccine+HBIG (n=59)
* P-values
Material characteristics
  Median age (years) 26 25
  Asian 100% 100%
  HBeAg-positive (baseline)  99% 100%
  Median HBV DNA
(baseline, Meq/mL)
1,936 2,390
Infant outcomes
  HBsAg-positive (week 52)
†  6% 12% 0.368
  Detectable HBV DNA (week 52) 20% 46% 0.003
* Final number of patients included, 
† Sensitivity analysis used.
HBIG, hepatitis B immunoglobulin; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen.
Table 4. FDA pregnancy categories for HBV antiviral therapy
FDA pregnancy category Description Antiviral
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in 
the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are 
no adequate and well-controlled studies in pregnant women, or animal studies which 
have shown an adverse effect, but adequate and well-controlled studies in pregnant 
women have failed to demonstrate a risk to the fetus in any trimester.
Telbivudine
Tenofovir
C Animal reproduction studies have shown an adverse effect on the fetus and there are no 
adequate and well-controlled studies in humans, but potential benefits may warrant 
use of the drug in pregnant women despite potential risks.
Adefovir
Entecavir
Lamivudine
D There is positive evidence of human fetal risk based on adverse reaction data from 
investigational or marketing experience or studies in humans, but potential benefits 
may warrant use of the drug in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is 
positive evidence of human fetal risk based on adverse reaction data from 
investigational or marketing experience, and the risks involved in use of the drug in 
pregnant women clearly outweigh potential benefits.
Interferon
FDA, Food and Drug Administration; HBV, hepatitis B virus.
23/59 (39%) infants in the control/ standard of care group. 
HBV DNA remained detectable in 20% infants in the lam-
ivudine group compared to 46% infants in the control group 
(P=0.003). No adverse events were reported. However, there 
were several important limitations in this study. An unexpectedly 
high rate of HBsAg seropositivity was seen in the standard 
of care group, suggesting that perhaps not all infants received 
immunoprophylaxis as per protocol. Additionally, infant loss 
to follow-up was significant. Taking this into account, rean-
alysis showed that there was only a trend but no significant 
difference in HBsAg seropositivity (6% lamivudine group 
vs. 12% control group).
16
More data regarding the safety and efficacy of telbivudine 
in preventing perinatal transmission of HBV are emerging. 
Pan et al. compared outcomes in 53 HBeAg-positive moth-
ers treated with telbivudine from second to third trimester 
until 4 weeks post-partum with 35 untreated control patients. 
In this study, baseline HBV DNA was > 6 log copies/mL and 
ALT >40 IU/mL but less than 10× upper limit of normal. All 
infants received active and passive immunization. At birth, 
4% and 23% the newborns were HBsAg-positive in the 
telbivudine and control groups, respectively (P<0.001).
17 
Although these data are promising, more studies with longer 
follow-up are needed.
Safety data on antiviral therapy are primarily derived 
from clinical studies and the antiretroviral pregnancy registry, 
a prospective registry mainly for HIV-positive individuals. 
As of 2010, only 112 women with HBV mono-infection were Yogeswaran and Fung. Chronic hepatitis B in pregnancy: unique challenges and opportunities  5
Figure 1. Algorithm for prevention of perinatal transmission of HBV infection.
* Appropriate counseling regarding treatment, treatment duration, potential side effects, monitoring on treatment, and cessation of therapy 
if breastfeeding is chosen.
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase; HBIG, hepatitis B immunoglobulin.
included. The bulk of the clinical data has been reported 
with lamivudine and tenofovir, as experience with other 
antiviral agents such as entecavir, adefovir and telbivudine 
remains limited. Overall rates of birth defects on antiviral 
therapy are estimated to be 2.7% live births, which is com-
parable to prevalence in the general population.
18 The FDA 
has classified entecavir, lamivudine, and adefovir as category 
C medications, whereas telbivudine and tenofovir are category 
B medications. Interferon has been classified as category X 
(Table 4).
The advantages of antiviral therapy during pregnancy 
include: potent antiviral suppression, relative safety and 
tolerability in pregnancy and, ultimately, a reduction in 
perinatal HBV transmission. Disadvantages include the risk 
of developing antiviral resistance in the mother depending on 
the antiviral agent used, contraindication to breastfeeding, 
and the risk of hepatitis flares upon discontinuation of therapy. 
In one study involving 31 HBeAg-positive and negative 
mothers, a postpartum flare defined as threefold increase in 
alanine amino transferase (ALT) occurred in 62% of lamivudine- 6  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011
treated mothers who discontinued therapy, compared with 
42% of untreated mothers.
19 Given limited long-term safety 
and efficacy data on antiviral therapy in pregnancy, the 
decision to initiate treatment should be made on a case-by-case 
basis. 
In clinical practice, HBV DNA levels are measured during 
the second trimester in all pregnant HBsAg-positive mothers 
(Fig. 1). If HBV DNA is ≥7 log IU/mL then prophylactic 
treatment beginning in the early third trimester with lamiv-
udine, tenofovir or telbivudine should be considered. 
Counseling should be provided regarding goals of treatment, 
treatment duration, potential side effects, overall safety in 
pregnancy for mother and fetus, monitoring on treatment 
and breastfeeding. If the mother decides to breast feed her 
infant, then all antiviral therapy must be discontinued at 
birth, in order to limit exposure to the infant. In addition, 
standard vaccination schedules are to be followed. Following 
cessation of therapy, mothers should be monitored with 
serial ALT and HBV DNA levels to detect asymptomatic 
treatment withdrawal flares, which may require subsequent 
treatment.
For HBsAg-positive carriers who develop active liver 
disease during pregnancy, standard treatment guidelines are 
applicable. The goal of treatment in this situation is to induce 
liver disease remission in the mother, in order to minimize 
the risk of preterm delivery. Persistent disease activity reflected 
by an elevated ALT, HBV DNA and/or presence of significant 
hepatic fibrosis (≥ F2 on Metavir) warrants early treatment, 
(ie. in the first trimester). Since long-term treatment may be 
required in this setting, treatment with tenofovir would be 
preferable due to overall safety and its very low risk of 
antiviral resistance.
20-22
SPECIAL CONSIDERATIONS 
Mode of delivery
Mode of delivery may also potentially affect the risk of 
perinatal HBV transmission, although different studies have 
yielded conflicting data. One study in China compared spon-
taneous vaginal delivery, vacuum extraction or forceps, and 
Caesarian section in terms of risk of HBV transmission. In 
total, 301 infants of HBsAg-positive mothers were included 
and all infants received HBIG at birth and hepatitis B vac-
cine shortly after birth. There was no difference in the rates 
of HBsAg positivity at birth between the 3 groups: 8.1%, 
7.7%, and 9.7% of infants, respectively. Rates of chronic 
infection were not significantly different between the groups 
during follow-up.
23 By contrast, a meta-analysis that included 
four randomized trials found that elective Caesarian section 
compared to vaginal delivery reduced mother-to-child HBV 
transmission (10.5% vs. 28%). Although the results were 
statistically significant, included studies had methodological 
flaws.
24 Therefore, most obstetric guidelines do not endorse 
routine use of Caesarian section to prevent perinatal trans-
mission of HBV.
Breast feeding
Transmission of HBV via breast milk is often another 
concern facing HBsAg-positive mothers. Early studies 
reported HBsAg, HBeAg and HBV DNA detection in 
colostrum. Higher HBsAg and HBeAg titres were found in 
mothers with high serum HBV DNA, suggesting that breast 
milk may be an important vehicle for transmission.
25 
However, in a population study of 369 vaccinated infants 
born to carrier mothers, HBsAg prevalence in breast-fed 
infants was 0/101 (0%) compared to 9/268 (3%) formula-fed 
infants.
26  Although this difference was not significant, it 
suggested that breast milk may have antiviral properties due 
to immunoglobulins and other proteins such as lactoferrin 
found in breast milk, which may explain the lower prevalence 
of HBsAg in breast-fed infants.
27 Previous studies had also 
shown no increased risk of transmission with breastfeeding.
28 
In view of the multiple benefits of breastfeeding, WHO recom-
mends breastfeeding for infants of HBsAg-positive mothers 
even in endemic areas where HBV vaccination may not be 
readily available.
29 However, the issue remains controversial 
and other organizations such as the American Academy of 
Pediatrics suggest that breast feeding not be withheld, provided 
that infants receive HBV vaccine and HBIG.
30
Nucleos(t)-ide therapy during breastfeeding is not 
recommended. Human data on lamivudine and other anti-
viral agents during breastfeeding in HBV mono-infection 
are not available.
27 One study that compared infant hemato-
logic and hepatic toxicity of maternal highly active anti-
retroviral therapy for HIV infection via breast milk found no 
significant difference between breastfed and formula-fed 
infants.
31 However, until more clinical data on the safety of 
tenofovir and other antiviral agents during breastfeeding are 
available, antiviral treatment during breastfeeding in HBV 
patients remains contraindicated.Yogeswaran and Fung. Chronic hepatitis B in pregnancy: unique challenges and opportunities  7
MATERNAL AND FETAL OUTCOMES
Even though CHB may be associated with significant 
mortality in non-pregnant chronic carriers, HBV infection 
during pregnancy does not appear to increase maternal or 
fetal mortality and morbidity. One large study that compared 
824 HBsAg-positive mothers to 6281 HBsAg-negative but 
otherwise similar control patients found no difference in 
preterm delivery, birth weight, neonatal jaundice, congenital 
anomalies, as well as perinatal mortality.
32 However, a more 
recent case-control study compared outcomes of 253 HBsAg- 
positive pregnant carriers to 253 matched controls. On 
multivariate analysis, HBsAg carriers had an increased risk 
of gestational diabetes mellitus, antepartum hemorrhage, 
and threatened preterm labour. This may be explained by 
active liver disease related to HBV infection during preg-
nancy in a proportion of patients included, which may have 
predisposed to the development of obstetric complications.
33 
However, mortality was not significantly different between 
the groups and further studies are needed to determine the 
relationship between CHB and maternal and fetal complications.
CONCLUSION
CHB in pregnancy presents a unique challenge, but also 
an important opportunity to interrupt perinatal transmission 
of HBV. Since maternal-fetal transmission is the major route 
of acquisition of HBV worldwide, strategies to eradicate 
HBV or to reduce global burden of disease must target this 
critical step in HBV disease propagation. To this end, 
population-based screening of all pregnant women for HBV 
and universal infant vaccination are required. Standard of 
care for the HBsAg-positive mother includes HBV vacci-
nation and HBIG in most centers in North America. Chronic 
HBV infection does not seem to increase risk of maternal- 
fetal morbidity and mortality. Additionally, standard vaginal 
delivery and breastfeeding do not appear to increase the risk 
of HBV transmission. Antiviral therapy using lamivudine, 
tenofovir or telbivudine should be reserved for those who 
have active liver disease during pregnancy and for those 
with very high viral load HBV DNA>7 log IU/mL in the 
third trimester, after an informed discussion with the preg-
nant HBV carrier. However, further large clinical trials are 
required to determine the role of antiviral prophylaxis in 
pregnancy. In summary, early recognition of the pregnant 
HBV carrier followed by treatment with safe antiviral agents, 
if indicated, and immunoprophylaxis will reduce perinatal 
HBV infection and its complications, while minimizing risk 
to the fetus/infant.
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